Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 5
2012 7
2013 14
2014 14
2015 11
2016 7
2017 7
2018 5
2019 7
2020 6
2021 6
2022 6
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Results by year

Filters applied: . Clear all
Page 1
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.
Scully M, Cataland SR, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De Winter H, Zeldin RK; HERCULES Investigators. Scully M, et al. N Engl J Med. 2019 Jan 24;380(4):335-346. doi: 10.1056/NEJMoa1806311. Epub 2019 Jan 9. N Engl J Med. 2019. PMID: 30625070 Free article. Clinical Trial.
Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia.
Kuter DJ, Efraim M, Mayer J, Trněný M, McDonald V, Bird R, Regenbogen T, Garg M, Kaplan Z, Tzvetkov N, Choi PY, Jansen AJG, Kostal M, Baker R, Gumulec J, Lee EJ, Cunningham I, Goncalves I, Warner M, Boccia R, Gernsheimer T, Ghanima W, Bandman O, Burns R, Neale A, Thomas D, Arora P, Zheng B, Cooper N. Kuter DJ, et al. Among authors: gumulec j. N Engl J Med. 2022 Apr 14;386(15):1421-1431. doi: 10.1056/NEJMoa2110297. N Engl J Med. 2022. PMID: 35417637 Clinical Trial.
Mechanobiology of cancerogenesis.
Raudenská M, Navrátil J, Gumulec J, Masařík M. Raudenská M, et al. Among authors: gumulec j. Klin Onkol. 2021 Spring;34(3):202-210. doi: 10.48095/ccko2021202. Klin Onkol. 2021. PMID: 34362256 English.
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.
Broome CM, McDonald V, Miyakawa Y, Carpenedo M, Kuter DJ, Al-Samkari H, Bussel JB, Godar M, Ayguasanosa J, De Beuf K, Rodeghiero F, Michel M, Newland A; ADVANCE Investigator Study Group. Broome CM, et al. Lancet. 2023 Nov 4;402(10413):1648-1659. doi: 10.1016/S0140-6736(23)01460-5. Epub 2023 Sep 28. Lancet. 2023. PMID: 37778358 Clinical Trial.
Caveolin-1 in oncogenic metabolic symbiosis.
Raudenska M, Gumulec J, Balvan J, Masarik M. Raudenska M, et al. Among authors: gumulec j. Int J Cancer. 2020 Oct 1;147(7):1793-1807. doi: 10.1002/ijc.32987. Epub 2020 Apr 21. Int J Cancer. 2020. PMID: 32196654 Free article. Review.
Unexpected therapeutic effects of cisplatin.
Raudenska M, Balvan J, Fojtu M, Gumulec J, Masarik M. Raudenska M, et al. Among authors: gumulec j. Metallomics. 2019 Jul 17;11(7):1182-1199. doi: 10.1039/c9mt00049f. Metallomics. 2019. PMID: 31098602 Review.
Metallothionein polymorphisms in pathological processes.
Raudenska M, Gumulec J, Podlaha O, Sztalmachova M, Babula P, Eckschlager T, Adam V, Kizek R, Masarik M. Raudenska M, et al. Among authors: gumulec j. Metallomics. 2014 Jan;6(1):55-68. doi: 10.1039/c3mt00132f. Metallomics. 2014. PMID: 24068159 Review.
Reduction of Doxorubicin-Induced Cardiotoxicity Using Nanocarriers: A Review.
Fojtu M, Gumulec J, Stracina T, Raudenska M, Skotakova A, Vaculovicova M, Adam V, Babula P, Novakova M, Masarik M. Fojtu M, et al. Among authors: gumulec j. Curr Drug Metab. 2017;18(3):237-263. doi: 10.2174/1389200218666170105165444. Curr Drug Metab. 2017. PMID: 28059036 Review.
91 results